Your browser doesn't support javascript.
loading
Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1.
Yang, Sijie; Yu, Yuanling; Jian, Fanchong; Yisimayi, Ayijiang; Song, Weiliang; Liu, Jingyi; Wang, Peng; Xu, Yanli; Wang, Jing; Niu, Xiao; Yu, Lingling; Wang, Yao; Shao, Fei; Jin, Ronghua; Wang, Youchun; Cao, Yunlong.
Affiliation
  • Yang S; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People's Republic of China.
  • Yu Y; Changping Laboratory, Beijing, People's Republic of China.
  • Jian F; Peking-Tsinghua Center for Life Sciences, Tsinghua University, Beijing, People's Republic of China.
  • Yisimayi A; Changping Laboratory, Beijing, People's Republic of China.
  • Song W; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People's Republic of China.
  • Liu J; Changping Laboratory, Beijing, People's Republic of China.
  • Wang P; College of Chemistry and Molecular Engineering Peking University, Beijing, People's Republic of China.
  • Xu Y; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People's Republic of China.
  • Wang J; Changping Laboratory, Beijing, People's Republic of China.
  • Niu X; School of Life Sciences, Peking University, Beijing, People's Republic of China.
  • Yu L; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People's Republic of China.
  • Wang Y; Changping Laboratory, Beijing, People's Republic of China.
  • Shao F; School of Life Sciences, Peking University, Beijing, People's Republic of China.
  • Jin R; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People's Republic of China.
  • Wang Y; Changping Laboratory, Beijing, People's Republic of China.
  • Cao Y; College of Future Technology Peking University, Beijing, People's Republic of China.
Emerg Microbes Infect ; 13(1): 2343909, 2024 Dec.
Article in En | MEDLINE | ID: mdl-38616729
ABSTRACT
The recent emergence of a SARS-CoV-2 saltation variant, BA.2.87.1, which features 65 spike mutations relative to BA.2, has attracted worldwide attention. In this study, we elucidate the antigenic characteristics and immune evasion capability of BA.2.87.1. Our findings reveal that BA.2.87.1 is more susceptible to XBB-induced humoral immunity compared to JN.1. Notably, BA.2.87.1 lacks critical escaping mutations in the receptor binding domain (RBD) thus allowing various classes of neutralizing antibodies (NAbs) that were escaped by XBB or BA.2.86 subvariants to neutralize BA.2.87.1, although the deletions in the N-terminal domain (NTD), specifically 15-23del and 136-146del, compensate for the resistance to humoral immunity. Interestingly, several neutralizing antibody drugs have been found to restore their efficacy against BA.2.87.1, including SA58, REGN-10933 and COV2-2196. Hence, our results suggest that BA.2.87.1 may not become widespread until it acquires multiple RBD mutations to achieve sufficient immune evasion comparable to that of JN.1.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Neutralizing / Immune Evasion / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 / Antibodies, Viral Limits: Animals / Humans Language: En Journal: Emerg Microbes Infect Year: 2024 Document type: Article Country of publication: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Neutralizing / Immune Evasion / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 / Antibodies, Viral Limits: Animals / Humans Language: En Journal: Emerg Microbes Infect Year: 2024 Document type: Article Country of publication: Estados Unidos